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Abstract
Biliary tract cancers are uncommon malignancies arising from biliary epithelium intrahepatically (peripheral cholangio-
carcinoma), in the extrahepatic bile duct, the gall bladder and the ampulla of Vater. Treatment has been challenging because
of late presentation, complex surgery, complex biliary obstruction with jaundice and a paucity of high quality data on which
to establish standard care. With improvements in imaging, biliary stenting, surgical management and the establishment of a
national investigational programme we hope to define the modern management of biliary tract cancers and enable a
platform for further research.
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Introduction
Biliary tract malignancy comprises adenocarcinomas
of biliary epithelium. These are geographically dis-
tinct, arising from biliary epithelium within hepatic
substance, known as peripheral cholangiocarcinomas,
at the hilum of the biliary tree, where they are known
as hilar cholangiocarcinomas, in the distal bile duct
and in the gall bladder (gall bladder carcinoma, GBC)
(Figure 1). It follows that biliary tract carcinomas are
anatomically and aetiologically distinct from pancrea-
tic or small bowel adenocarcinomas, although histori-
cally they are often managed similarly.
The management of biliary tract cancer (BTC) has
changed dramatically in the last 20 years. The
obstacles to progress have been the poor performance
status of these patients at the time of presentation and
the lack of conclusive histological diagnosis. Improve-
ments in biliary drainage have rendered patients
sufficiently fit to allow more sophisticated imaging
and histological diagnosis followed by consideration
of novel innovative treatments such as photodynamic
therapy.
Incidence and aetiology
Biliary tract cancers are uncommon, the incidence
being approximately 1500 cases per year [1]. The risk
factors fall primarily into two groups: genetic and
inflammatory (Table I).
The incidence of BTC in the western world is
primarily related to gallstones and primary sclerosing
cholangitis (PSC), whereas that in the Far East is
related to infective causes. The incidence worldwide is
rising and appears to be independent of an associated
increase in PSC (Figure 2) [2]. The rise is not
associated with any changes in the proportion of
patients with unstaged cancer, localized cancer, his-
tological confirmation, tumour size or overall survival.
These data suggest that this is a true increase related
to an environmental factor as yet unknown.
The presentation of BTC is dependent on the site
of the tumour. These symptoms would clearly be
guided by predisposing factors such as PSC but in
general, intrahepatic tumours present with systemic
and advanced features whereas biliary and distal
tumours present with obstructive jaundice (Table II)
[3].
Pathology
Cholangiocarcinoma is often associated with inactiva-
tion of tumour suppressor genes, for example, p53,
APC, Smad-4, bcl-2 and p16 [46]. Mutations in
oncogenes have also been described, for example,
K-ras , c-myc , c-erbB-2 and c-neu. These data place
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BTC in the family of gastrointestinal carcinomas
with a complex molecular profile and malignant
development. Molecular profiling may further define
the disposition of BTC among gastrointestinal carci-
nomas and provide insights into aetiology, mole-
cular pathogenesis and potential molecular interven-
tions.
Imaging
Although the initial imaging investigation for patients
with potential BTC is an ultrasound, patients nor-
mally proceed to magnetic resonance cholangiopan-
creatography (MRCP) or endoscopic or percutaneous
cholangio-pancreatography (ERCP-PTC). The latter
techniques allow for cytological sampling (positive in
about 30%), allow stent insertion and in may cases
will determine operability. Computed tomography
(CT) and magnetic resonance (MR) scanning are
often used in parallel to define the intrahepatic extent
of the tumour and there is little agreement as to a
single optimal imaging investigation [7]. A key aim
of any imaging would be to identify appropriate
lesions for biopsy and histological confirmation.
Endoscopic ultrasound provides a useful guide for
fine needle aspiration [8] and positron emission
tomography using fluorodeoxyglucose (FDG-PET)
can be helpful, particularly in upstaging potentially
resectable disease [9].
Hilar cholangiocarcinomas often infiltrate along
biliary epithelium, into lymphatics and perineu-
ral spaces making staging, particularly preoperative
staging, difficult. Endoscopic retrograde cholangio-
Figure 1. Distribution of biliary tract malignancies. 1, peripheral
cholangiocarcinoma; 2a and 2b, right and left hepatic ducts,
respectively; 3, confluence of right and left hepatic ducts (perihilar,
Klatskin tumours); 4, common hepatic duct; 5, gall bladder; 6,
cystic duct; 7, common bile duct.
Figure 2. Incidence of biliary tract cancer. From Patel [2].
Table I. Risk factors for biliary tract cancer.
. Age (65% greater than 65 years)
. Smoking
. Primary sclerosing cholangitis (PSC)
. Chronic gallstones
. Bile duct adenoma and biliary papillomatosis
. Choledochal cysts (5% will transform)
. Liver flukes
. Chronic typhoid carriers











Jaundice 0* 91 87 84
Abdominal
pain
61$ 36 27 35
Weight loss 11 36 30 33
Fever 6 14 2 10
From Nakeeb et al. [3].
*pB0.01 vs others.
$pB0.05 vs others.
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pancreatography (ERCP) and percutaneous trans-
hepatic drainage (PTD) are recommended for the
added anatomical information they can provide. PTD
is better traversing tight malignant strictures [10].
Standard staging algorithms include CT of the
chest, abdomen and pelvis to exclude metastatic
spread and can be used to calculate remnant tu-
mour-free liver volumes for extended liver resections.
MRCP offers a non-invasive method of defining the
extent of intrahepatic biliary involvement. Doppler
ultrasound can define vascular involvement, although
some clinicians still resort to invasive techniques such
Figure 3. Imaging modalities. (a) Ultrasound. (b) Endoscopic cholangio-pancreatography (ERCP). (c) CT scan showing dilated biliary
tree on the left side with parenchymal atrophy. (d) MRI scan demonstrating mass at the hilum. (e) PET scan demonstrating node and
peritoneal disease.
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as angioportography. CT has a low sensitivity for
peritoneal disease and therefore preoperative laparo-
scopy is usually included (Figure 3c).
Therapeutic options
The current therapeutic options are biliary stenting,
surgery, radiotherapy (RT), photodynamic therapy
(PDT) and chemotherapy. This review will not
consider biliary stenting.
Surgery (Table III)
Radical surgical resection offers the only chance of
long-term survival in the treatment of BTC but
unfortunatelyB20% of presenting patients are suita-
ble for surgery. The aim of any proposed surgical
procedure is to achieve complete tumour removal
together with clear resection margins (R0) [11].
Peripheral cholangiocarcinoma can be adequately
removed by segmental liver resection and lower third
bile duct cholangiocarcinoma (Figure 1) by pancrea-
ticoduodenectomy. Hilar cholangiocarcinoma repre-
sents a formidable challenge both in terms of defining
preoperatively the extent of tumour extension within
the intrahepatic biliary tree and as a technical
challenge to achieve adequate surgical clearance.
The anatomy of the biliary tract makes this a
particular challenge.
Extended right hepatectomy (segments 48) with
routine caudate lobe resection (segment 1) has been
shown to achieve the largest benefit with respect to
resectability [12] (Table IV). Most tumours including
Bismuth types IIIa/b (extension into right/left hepatic
ducts) and IV (both ducts) can be managed with this
procedure, as long as adequate segment II/III remnant
volumes have been achieved with right portal vein
embolization and biliary decompression of the left
liver. This represents a major resection with an
associated high postoperative morbidity/mortality
rate for which patients need to have been assessed to
ensure adequate physiological reserve by an experi-
enced anaesthetist and they need to be well counselled
on the potential risk. Postoperative liver insufficiency
can be avoided by ensuring remnant volumes of at
least 25% of the total volume and therefore portal vein
embolization is a useful adjunct to cause atrophy of
the ipsilateral resection side and hypertrophy of the
planned remnant liver.
An understanding of hilar anatomy establishes
right-sided resections as preferable to left for two
reasons. First, the confluence of the hepatic ducts lies
posterior to the right side of the hepatoduodenal
ligament, increasing the potential for right hepatic
artery involvement. Second, the length of the extra-
hepatic left hepatic duct proximal to second-order
segmental tributaries compared with the relatively
short right duct increases the likelihood of an R0
resection if this is the intended anastomotic site. An
extended right resection is also a technically easier
procedure with a natural transaction line provided by
the falciform ligament.
The 5-year survival varies between 29% and 100%
for those patients with completely resected disease,
suggesting that there is significant variability both in
surgical technique and methodology of reporting
(Figures 4 and 5, Table V). Neuhaus and colleagues
[13] have achieved R0 5-year survival rates of 65%,
advocating more radical resections to increase the
Table III. Procedures at surgery.
Site Operation
Peripheral Lobectomy or extended lobectomy [13] with
lymphadenectomy [14]
Hilar Type 1: Extrahepatic bile duct resection with Roux
loop reconstruction Types 24: Hepatectomy




Table IV. Extent of resection of patients with hilar cholangiocarci-






Central resection only 1 0
Right hepatectomy 1 8
Right hepatectomy with extension
to segment 4
1 1
Right trisectionectomy 3 11
Left hepatectomy 5 5
Left hepatectomy with extension
to segment 4
0 2
Left trisectionectomy 1 0




Concomitant portal vein resection 3 8
From Liu et al. [12].
Figure 4. Comparison of survival between resections with and
without marginal involvement. A significant difference was found
(p0.0018). From Kitagawa et al. [16].
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likelihood of complete tumour excision and negative
margins. In certain circumstances therefore they have
included removal of the portal vein confluence and
reconstruction of the left portal vein branch together
with an extended right resection. This enables the
surgeon to employ a ‘no touch technique’, avoiding
the tumour and its immediate surrounding tissue.
This has been achieved with acceptable perioperative
mortality figures (8% 60-day death rate). Other
factors that independently affected outcome and
were significant on multivariate analysis included
perineural sheath infiltration, lymphangiosis carcino-
matosa and histopathological grading.
Transplantation
Outcomes are poorer after transplantation for cholan-
giocarcinoma than for any other diagnosis [10]. Single-
centre reports demonstrate that careful patient selec-
tion of patients with early stage disease with the use of
neoadjuvant therapies including chemoradiotherapy
may produce outcomes approaching those of other
diagnoses for which transplantation is used [15].
Gall Bladder Carcinoma
Surgery for GBC is guided by similar strategies. As for
cholangiocarcinoma, lymph node involvement is com-
mon at approximately 50% and there is peritoneal and
distant metastasis of 10-20% at presentation. Perito-
neal and distant metastasis increases to 50% with
serosal involvement of the gall bladder, thus careful
preoperative evaluation of the extent of gall bladder
involvement is critical. Those tumours limited to the
mucosa of the gall bladder (T12 tumours) should be
treated with cholecystectomy. Any more advanced
tumours should be treated with aggressive lymphatic
and nodule resection, although there are few rando-
mized data to suggest this improves survival. There
are only two major surgical series of GBC (Table VI).
There is a single adjuvant study reporting an
improvement in survival for GBC patients receiving
a postoperative regimen of mitomycin C and fluor-
ouracil; however, the numbers are small and the data
need confirmation with a more commonly accepted
regimen [26]. The value of adjuvant therapy will be
examined in a UK National Cancer Research Institute
study randomizing patients between surveillance and
adjuvant chemotherapy.
Radiation therapy
All therapeutic modalities are hampered by poor data
supporting their use and RT is no exception. The
published data describe series of patients (B40 in
number) treated with adjuvant [27] and palliative [28]
radiation. The evidence would not support standard
use of either modality. There are similarly limited
datasets describing the use of brachytherapy [29,30],
intraoperative radiation [31] and chemoradiation
[32,33]. The conclusion is that RT should only be
considered in the context of a clinical trial.
Photodynamic therapy
Photodynamic therapy (PDT) is a two-stage treat-
ment. A photosensitizer is given systemically and
taken up preferentially by tumour. The exact mechan-
ism of this preferential uptake is not completely
understood. Most photosensitizers are modified hae-
matoporphyrins that absorb light at a specified
wavelength following tumour localization. Normal
tissue is unaffected as it does not take up photo-
sensitizer nor is it subsequently exposed to light. The
differential in terms of treatment effect is therefore
both biological and anatomical. There has been
increasing use of PDT concurrent with improved
photosensitizers. The technology required to deliver
PDT is not sophisticated, requiring only standard
ERCP equipment and a relatively cheap light source.
Figure 5. Survival according to nodal status in 110 patients with
hilar cholangiocarcinoma who underwent resection with regional
and para-aortic lymphadenectomy (all deaths included). Group I,
patients without lymph node metastasis; group II, patients with
regional lymph node metastasis; group III, patients with para-aortic
node metastasis. *Log-rank test. From Madariaga et al. [20].
Table V. 5-year survival following surgery for cholangiocarcinoma.
Reference No.
5-year
survival (%) R0 (%)
Bartlett et al. 1996 [19] 23 58 100
Nakeeb et al. 1996 [3] 294 1144 5091
Madariaga et al. 1998 [20] 62 835 2950
Jarnagin et al. 2001 [21] 160 30 50
Huang et al. 2004 [22] 31 33 
Rea et al. 2004 [23] 46 26 80





survival (%) R0 (%)
Tsukada et al. 1996 [24] 106 33 70
Puhalla et al. 2002 [25] 60 18 75
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There is a thermal cytotoxic effect resulting in tissue
necrosis, the extent of which depends on the type of
photosensitizer used [34].
The defining study on PDT in CCA was performed
by Marian Ortner and colleagues [35]. Thirty-nine
patients were randomized to receive stenting or
stenting with PDT. Many patients had advanced
disease and a poor performance status that precluded
standard palliation with chemotherapy. The study 
which originally planned to recruit 200 patients  was
terminated early by the data monitoring committee,
as there was a dramatic difference in the observed
survival. PDT conferred a survival advantage of 10
months (493 vs 98 days). In addition, there was a
group of 20 patients who received PDT despite being
ineligible who had a similar survival to those treated
with PDT, suggesting that this PDT effect was real.
The data have been criticized for the small numbers
as well as the poor survival of the control group (most
were jaundiced and did not receive palliative treat-
ments) and it is unlikely that clinical practice will be
changed by 20 patients. However, these are stimulat-
ing data with impressive survival benefit achieved with
minimum toxicity (mild photosentivity in 10%). In
addition, the patients have an improvement in their
bilirubin, an improvement in their quality of life and
reduction in subsequent life- threatening events,
particularly cholangitis. The potential of PDT will
be examined in a UK National Cancer Research
Institute study randomizing patients between stenting
alone and PDT with stenting.
Palliative chemotherapy
There is no standard palliative chemotherapy for BTC
as the data derive from small, mostly unrandomized
series treating mixed populations and reported in
inconsistent formats. Many agents have been tried
and are reported extensively elsewhere [36] but most
studies have used fluoropyrimidine- or gemcitabine-
based schedules. In a malignancy for which estimates
of change in tumour size are challenging, overall
survival in a randomized context is likely to be the
most reliable endpoint to estimate efficacy. The low
incidence of BTC means that such trials are difficult to
establish and to date studies have not been designed to
reliably report survival differences (Table VII).
All studies have accruedB60 patients and none
were powered for survival. In addition, the two
earlier studies by Glimelius et al. [37] and Takada
et al. [38] included patients with pancreas cancer.
These data cannot recommend a standard palliative
treatment for BTC. There are a plethora of non-
randomized phase II studies that are difficult to
interpret. This is highlighted by a dramatic difference
between the response rates (957%) yet a relatively
small difference in median survival (79 months)
[42]. However, it is clear that there is activity with
fluropyrimidine- and gemcitabine-based regimes and
the confirmation of their comparative benefit rather
than the demonstration of the benefit of palliative
chemotherapy over best supportive care should be
the aim of current research programmes.
Table VII. Randomized studies using palliative chemotherapy in BTC.
Reference No. of patients Survival (months) Chemotherapy
Glimelius et al. [37] 37 6 vs 2.5 5FU/Etop vs BSC
Takada et al. [38] 31 6 vs 3 5FU/Dox/MMC vs BSC
Kornek et al. [39] 51 6.7 vs 9.3 MMC/Gem vs MMC/Capecitabine
Ducreux et al. [40] 58 5 vs 8 5FU vs Cis/5FU
Rao et al. [35] 50 12 vs 9 FELV vs ECF
Valle et al. [41] 86  Gemcitabine vs Gemcitabine-Cis
BSC, best supportive care; Cis, cisplatin; Dox, doxorubicin; Etop, etoposide;
5-FU, 5-fluorouracil; MMC, mitomycin C.
Table VIII. Some recent studies in BTC.
Trial identifier Compounds Phase Details
SWOG-S0202 Gemcitabine and capecitabine II 57 patients Median survival 7 months
CWRU-2299 Rebeccamycin analogue II 637 patients Indolocarbazole compounds Recruitment
completed
UCCRC-11045 BMS-247550 (Ixabepilone) II 2150 patients Novel epothilone Recruitment completed
FCCC-03042 Bortezomib II 35 patients Proteasome inhibitor
NYWCCC-NCI-6254 Triapine and gemcitabine II 78 patients Ribonucleotide reductase inhibitor
SWS-SAKK-44/02 Capecitabine and gemcitabine II 1944 patients Recruitment completed
NCCTG-N9943 Gemcitabine and pemetrexed II 85 patients
OSI-904-202 OSI7904L versus 5-FU/LV RII 58 patients Liposome encapsulated Thymidylate synthase
inhibitor Recruitment completed
NCT00090025 XL119 (becatecarin) versus
5-fluorouracil (5-FU)
RIII 600 patients Topoisomerase II inhibitor Terminated early
because of 5-FU advantage
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The largest study reported in abstract form in 2006
is that of Valle and colleagues [42]. Although there
appeared to be an improvement in 6 month DFS
(57% vs 48%) in favour of the combination of
gemcitabine and cisplatin vs gemcitabine, the study
was not powered to provide a statistically meaningful
result and this benefit may be offset by a significant
increase in fatigue (29% vs 9%). Patients received
more treatment on the combination arm (23.1 vs 15.0
weeks), suggesting that there were fewer disease-
related treatment delays and reasons for stopping on
the combination arm. The UK National Cancer
Research Institute has expanded this study to provide
a statistically meaningful survival endpoint with
quality of life assessments. This will provide the
largest dataset in BTC research and define the
palliative chemotherapy for BTC.
Current studies in advanced BTC
Table VIII details some recent studies in BTC.
Increasingly BTC are being recognized as a tumour
type in which novel agents may be used.
Key questions in the management of BTC
The key questions for the management of BTC are as
follows:
1. Is more aggressive surgery justified? The non-
randomized data suggest that some patients are
cured by more extensive hepatic and nodal
resection but this needs to be formally tested.
2. Does adjuvant chemotherapy improve survival
following surgery? The data from Takada et al.
[38] suggest a benefit and benefits have been
demonstrated in all major tumour types.
3. Does improved biliary drainage with PDT im-
prove survival? The early data from Ortner need
to be validated [35]. The feasibility of conduct-
ing PDT has been confirmed in a phase II NCRI
study [43].
4. What is the optimum chemotherapy schedule?
There is consensus among oncologists that
palliative chemotherapy is of benefit but the
optimum schedule needs to be formally identi-
fied.
5. Is radiation of value?
Table IX describes the portfolio of National Cancer
Research Institute (UK) trials now available. All
studies are powered for survival and this portfolio is
accompanied by a tissue collection module. It is
hoped that the studies will help define the twenty-
first century management of BTC.
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